Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety/Tolerability of GrassMATAMPL
2005-004959-35Phase 3Completed
- Sponsor
- Allergy Therapeutics PLC
- Start
- Apr 2006
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in grass pollen allergy, seasonal allergic rhinitis (SAR), allergic conjunctivitis (AC) and 1 more comparing Grass MATA MPL with Placebo (2 arms). Primary endpoint: Combined eye and nose symptom/medication score during 4 peak weeks of grass pollen season. Started Apr 2006; status: completed.
02
Drugs
Grass MATA MPL
03
Conditions
grass pollen allergyseasonal allergic rhinitis (SAR)allergic conjunctivitis (AC)asthma
Beyond the preview
Go deeper on 2005-004959-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004959-35.